analogue insulin

(redirected from analog insulin)

analogue insulin

A term of art for a synthesised insulin in which insulin’s amino acid sequence is altered by genetic engineering to alter absorption, delivery (e.g., to reduce clumping) or provide another desired characteristic.

Examples
Humulin (rapid absorption), Glargine (constant release over 24 hours).
 
Results
Evidence-based assessment indicates that they are much more expensive and do not substantially improve outcomes.
References in periodicals archive ?
The insulin market is broadly categorized into six major types based on the product type such as rapid acting analog insulin devices, longer acting analog insulin devices, pre-mixed insulin, pre-mixed analog, short acting insulin, and intermediate insulin.
Paras Biopharmaceuticals has developed and is now offering clinical development and marketing collaboration for the following Biosimilars: Recombinant Teriparatide (Forteo[R] Biosimilar), Recombinant Anakinra (Kineret[R] Biosimilar), Analog Insulin Aspart[R], Recombinant Rasburicase (Elitek[R] / Fasturtec[R] Biosimilar) and Recombinant Romiplostim (N-plate[R] Biosimilar).
Heise, "Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart," Diabetes Care, vol.
(26) The formation of stable dihexamers enables coformulation of IDeg with the glucagon-like peptide-1 receptor agonist liraglutide and the rapid-acting analog insulin aspart.
Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo.
On yil once tip 1 DM tanisi konan fakat duzenli kontrollere devam etmeyen 38 yasinda kadin hasta; sabah 36u, aksam 26u bifazik hizli etkili analog insulin karisimi kullanmaktaymis.
Time-action profile of the long-acting insulin analog insulin glargine (HDE901) in comparison with those of NPH insulin and placebo.
The median bioavailability of TI was approximately 24% relative to SC analog insulin. The PD effect was assessed by the glucose infusion rate (GIR) required to maintain euglycemia (90 [+ or -] 10 mg/dL) for 4 hours postdosing in this glucose clamp study.
* Biosimilars comprised of osteoporosis recombinant Teriparatide, analog insulin and therapeutic fragment of monoclonal antibodies